Analysis of the Mechanism and Safety of Bisphosphonates in Patients with Lung Cancer and Bone Metastases
Authors:
Open Access
- 13 December 2021
- journal article
- retracted article
- Published by Hindawi Limited in Computational and Mathematical Methods in Medicine
- Vol. 2021, 1-6
Abstract
Objective. To explore the mechanism and safety of bisphosphonates in patients with lung cancer and bone metastases. Method. A total of 104 patients with lung cancer and bone metastases in our hospital were selected and randomly divided into two groups: control group ( ) and research group ( ). Chemotherapy was given to the control group, and the research group was treated with bisphosphonate drugs. The quality of life, HAMA, HAMD score, VAS score, treatment effect, serum calcium and KPS score, inflammatory factor levels, and immune function were compared between the two groups. Result. The quality of life in both groups was significantly increased ( ). The HAMA and HAMD scores of the research group decreased significantly than those of the control group after treatment ( ). The VAS scores of the two groups were significantly reduced ( ). The effective rates of treatment in the control group and the research group were 81.5% and 96.0%, respectively. Serum calcium was significantly decreased, and KPS score was significantly increased at weeks 1 and 6 after treatment, and the change was more obvious in the research group ( ). The levels of inflammatory factors in the two groups were significantly reduced, and the immune indicators were significantly increased. Conclusion. Bisphosphonates have good effect on patients with lung cancer and bone metastases, which can improve anxiety and depression, reduce pain score, improve serum calcium level and immune function, and reduce inflammatory response. Therefore, bisphosphonate drug therapy is worth widely used.Keywords
This publication has 25 references indexed in Scilit:
- Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort studyInternational Journal of Cancer, 2019
- Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor‑treated patients with non‑small cell lung cancer exhibiting bone metastasisOncology Letters, 2019
- Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in GermanySupportive Care in Cancer, 2019
- Cost–effectiveness of standard utilization of zoledronic acid for bone metastases from advanced lung cancer in ChinaJournal of Comparative Effectiveness Research, 2019
- Metastatic bone disease: Pathogenesis and therapeutic optionsJournal of Bone Oncology, 2019
- Symptoms of and Palliative Treatment for Unresectable Skin CancerCurrent Treatment Options in Oncology, 2019
- Dedicator of Cytokinesis 4: A Potential Prognostic and Predictive Biomarker Within the Metastatic Spread of Breast Cancer to BoneCancer Informatics, 2019
- Effect of advanced age and/or systemic medical conditions on dental implant survival: A systematic review and meta‐analysisClinical Oral Implants Research, 2018
- Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for OsteosarcomaCurrent Drug Targets, 2018
- Renal Impairment Hampers Bisphosphonate Treatment in a Quarter of Lung Cancer Patients with Bone MetastasisBasic & Clinical Pharmacology & Toxicology, 2017